2395
SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.
新日本科学
- Industry
- Services
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
15,110,548
Mar 2022
17,748,482
Mar 2023
25,090,903
Mar 2024
26,450,468
Mar 2025
32,413,807
Operating profit(thousand JPY)
Mar 2021
2,529,534
Mar 2022
4,195,609
Mar 2023
5,245,233
Mar 2024
4,162,359
Mar 2025
2,985,215
Operating profit margin(%)
Mar 2021
16.74
Mar 2022
23.64
Mar 2023
20.9
Mar 2024
15.74
Mar 2025
9.21
Profit before tax(thousand JPY)
Mar 2021
4,175,563
Mar 2022
8,183,311
Mar 2023
7,759,612
Mar 2024
6,974,444
Mar 2025
6,013,099
Profit(thousand JPY)
Mar 2021
3,661,855
Mar 2022
7,127,629
Mar 2023
6,060,057
Mar 2024
5,531,261
Mar 2025
4,924,848
Total assets(thousand JPY)
Mar 2021
36,972,404
Mar 2022
39,312,655
Mar 2023
57,242,205
Mar 2024
76,302,347
Mar 2025
92,416,508
Cash and cash equivalents(thousand JPY)
Mar 2021
7,279,835
Mar 2022
4,548,792
Mar 2023
9,197,694
Mar 2024
10,274,773
Mar 2025
11,843,986
Cash flows from operating activities(thousand JPY)
Mar 2021
4,746,687
Mar 2022
5,952,778
Mar 2023
4,004,019
Mar 2024
2,106,732
Mar 2025
7,035,243
Cash flows from investing activities(thousand JPY)
Mar 2021
-268,657
Mar 2022
-4,268,545
Mar 2023
-5,930,578
Mar 2024
-6,907,735
Mar 2025
-11,691,221
Cash flows from financing activities(thousand JPY)
Mar 2021
-2,471,074
Mar 2022
-4,911,983
Mar 2023
6,266,243
Mar 2024
5,318,656
Mar 2025
5,914,147
Return on equity(%)
Mar 2021
22.9
Mar 2022
40.4
Mar 2023
26.5
Mar 2024
18.3
Mar 2025
13.3
Equity ratio(%)
Mar 2021
42.6
Mar 2022
49.8
Mar 2023
45.8
Mar 2024
44.7
Mar 2025
43.3
Earnings per share(JPY per share)
Mar 2021
87.95
Mar 2022
171.2
Mar 2023
145.56
Mar 2024
132.86
Mar 2025
118.29
Net assets per share(JPY per share)
Mar 2021
377.94
Mar 2022
469.85
Mar 2023
629.6
Mar 2024
819.42
Mar 2025
961.34
Dividend per share(JPY per share)
Mar 2021
20
Mar 2022
40
Mar 2023
50
Mar 2024
50
Mar 2025
50
Payout ratio(%)
Mar 2021
22.74
Mar 2022
23.36
Mar 2023
34.35
Mar 2024
37.63
Mar 2025
42.27
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.